Elevation in oxidative stress level can damage cell and tissue….

This study systemically reviewed randomized controlled trials and observational studies to evaluate whether actual exposure of metformin can be associated with cancer and cancer mortality in type 2 diabetes patients….

Women diagnosed with Polycystic Ovary Syndrome are at an increased risk of type 2 diabetes and cardiovascular disease….

Promising results from IDegLira and the DUAL I trial…. Novo Nordisk’s new drug IDegLira is a fixed-ratio combination of insulin degludec and the glucagonlike perptide-1 (GLP-1) agonist liraglutide. It combines the effects of insulin degludec and liraglutide in a once daily injection. In the Dual Action of Liraglutide and Insulin …

GLP-1 agonist may prove beneficial to type 1 diabetes….

The cost of treating a type 2 diabetes patient throughout their lifetime is estimated to be $85,500….

Diabetes and end stage renal disease (ESRD), when together, contribute to increased cardiovascular (CV) events, such as acute myocardial infarction and stroke….

Do metabolically healthy obese individuals have higher risks for diabetes and CVD?…

How does diet, alcohol consumption, and sodium intake affect incidence or progression of CKD in diabetic patients?…

We’ve been bringing you these special newsletters about the SGLT2 inhibitors and hopefully they are helping you see how these new medications can be part of your patient treatment plan. For this edition, we have gone to some of the patients on the only SGLT2 Inhibitor currently available, Invokana. In …